Takeda (NYSE: TAK) HR chief sells 12,980 ADS, keeps 40,049

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD (TAK) reported an insider share sale by Chief Human Resources Officer Nicola Deidre Petal Greenway. On 2026-08-18, she sold 12,980 American Depositary Shares at $18.1139 per share in an open market or private transaction, and 40,049 ADS remain held directly.

Insider Trade Summary

Net Seller: 12,980 shares

Net Sell 1 txn

Insider Greenway Nicola Deidre Petal

Role Chief Human Resources Officer

Sold 12,980 shs ($235K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	12,980	$18.1139	$235K

Holdings After Transaction: American Depositary Shares — 40,049 shares (Direct)

Key Figures

Shares sold: 12,980 American Depositary Shares Sale price per share: $18.1139 per American Depositary Share Shares held after transaction: 40,049 American Depositary Shares

3 metrics

Shares sold 12,980 American Depositary Shares Non-derivative sale on 2026-08-18 by Chief Human Resources Officer

Sale price per share $18.1139 per American Depositary Share Price reported as per-share for the 12,980 ADS sale

Shares held after transaction 40,049 American Depositary Shares Direct ownership position following the reported sale

Key Terms

American Depositary Shares, non-derivative, open market or private transaction

3 terms

American Depositary Shares financial

"The reported security is American Depositary Shares of Takeda Pharmaceutical."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

non-derivative financial

"The transaction is classified as non-derivative, meaning it involves the shares themselves."

open market or private transaction financial

"Transaction code S denotes a sale in open market or private transaction."

FAQ

What insider transaction did TAK (Takeda Pharmaceutical) report for Nicola Deidre Petal Greenway?

Takeda reported that Nicola Deidre Petal Greenway, its Chief Human Resources Officer, sold 12,980 American Depositary Shares on 2026-08-18. The sale was reported as an open market or private transaction under transaction code S.

How many TAK American Depositary Shares were sold in this Form 4 filing?

The filing reports a sale of 12,980 American Depositary Shares of Takeda Pharmaceutical. These shares were sold in a single non-derivative transaction on 2026-08-18, classified under transaction code S, indicating a sale in the market or a private transaction.

At what price were the TAK shares sold in Nicola Greenway’s transaction?

The shares were sold at a price of $18.1139 per American Depositary Share. This price is reported on a per-share basis for the 12,980 ADS sold on 2026-08-18 in a non-derivative transaction.

How many TAK shares does Nicola Greenway hold after this reported sale?

After the reported sale, Nicola Deidre Petal Greenway holds 40,049 American Depositary Shares of Takeda directly. This post-transaction holding figure is reported as the total shares following transaction in the Form 4 data.

Was the TAK insider sale by Nicola Greenway made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmed (set to false). There is no linked footnote stating the trade was made pursuant to a Rule 10b5-1 trading plan in the provided data.

What type of security did Nicola Greenway trade in this TAK Form 4?

Nicola Greenway traded American Depositary Shares of Takeda Pharmaceutical. The Form 4 classifies this as a non-derivative security transaction, distinguished from options or other derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 04:16 PM Accepted by SEC EDGAR 08/19/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenway Nicola Deidre Petal

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/18/2026		S		12,980	D	$18.1139	40,049	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Samuel Ntonme, by power of attorney, for Nicola D. Greenway	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)